Pharma: how the sector works
The pharmaceutical value chain end to end: discovery, clinical trials, approval, manufacturing, and commercialization, plus who the players are and how money is made.
This block gives you the operating logic of the pharmaceutical industry, from molecule discovery to patient access. You will see how R&D, manufacturing, regulatory approval, market access and distribution connect into a single value chain, and why timelines and capital intensity are so extreme compared to other sectors. You will map the major players, from big pharma and biotech to CMOs, PBMs, payers and regulators, and understand where profit pools concentrate and why patents matter so much. You will learn the regulatory backbone (FDA, EMA, ICH, GxP) that shapes every commercial decision. Finally, you will get the numbers, acronyms and benchmarks needed to read this sector fluently and assess opportunities or risks quickly.
What you'll master
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
- Use key market figures, ratios and acronyms to quickly assess a pharma company, deal or market opportunity
Key terms
Modules
Covers how drugs move from research to patients and how value is created along the chain.
Examines the key players and power struggles shaping pricing, innovation and market access.
Explains the laws, approval processes and compliance rules governing pharmaceutical activity.
Provides the numbers, acronyms and benchmarks needed to analyse the sector fluently.
Latest articles
Recent articles from the blog that apply to Pharmaceuticals.
- FinancePharma partnership terms that protect your pipeline when the science goes sidewaysMilestone-based deals are how most biotech companies survive long enough to see their drug approved, but poorly structured agreements can leave a CFO holding the downside while the partner captures the upside. This playbook shows how to build deal terms that align incentives across a decade-long development arc.
- DataOne HCP, six records: why identity resolution is pharma's most expensive data problemA single cardiologist can exist as six different entities across a pharma company's CRM, claims data, and prescriber analytics systems, and none of them match. Until identity resolution works in practice, every downstream decision, from sampling allocations to pharmacovigilance reporting, is built on a fractured foundation.
- FinanceRisk-adjusted NPV for pre-revenue biotech pipelines: how the math actually worksMost valuation frameworks break down when applied to a drug candidate that has never generated a dollar of revenue and may never reach patients. Risk-adjusted NPV fixes that problem, but only if you understand what the model is actually doing and where it quietly fails.
- DataGxP integrity, 21 CFR Part 11, and GDPR: what happens when three regulatory regimes collidePharma CDOs operate at the intersection of three distinct regulatory systems, each with its own logic, its own enforcement body, and its own definition of what a data record actually is. Understanding where those systems conflict, not just where they overlap, is the difference between audit readiness and a consent notice architecture that accidentally destroys your audit trail.
- DataPrivacy-enhancing technologies in practice: the hype is ahead of the implementationPrivacy-enhancing technologies have generated serious boardroom attention, and the underlying science is real. But the gap between pilot programs and production-grade deployment is wider than most CDOs are being told.